^
Association details:
| Biomarker: | KRAS G12D + KRAS G12V |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Augtyro (repotrectinib) (ALK inhibitor, Multi-tyrosine kinase inhibitor, ROS1 inhibitor, Trk inhibitor) + avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1104 - Repotrectinib increases effectiveness of MEK inhibitors in KRAS mutant cancer models
Published date:
03/10/2021
Excerpt:
Repotrectinib/trametinib and repotrectinib/VS-6766 combinations yielded significant effects on cancer cell viability in NSCLC and pancreatic patient-derived spheroid models harboring KRASG12D and KRASG12V mutations....the combination of repotrectinib with MEKi can repress the mutant KRAS signaling network to achieve more potent and durable anti-tumor activity and warrants clinical investigation in patients with KRASG12D and KRASG12V mutant cancers.
